Clinical Trial Update: A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study sponsored by AVEO Pharmaceuticals in patients with advanced lymphomas and multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Malignant Solid Tumor, Lymphomas | Phase 1 | Status: COMPLETED